Trovafloxacin mesilate

Generic Medicine Info
May be taken with or without food.
Severe hepatic cirrhosis, hypersensitivity to quinolones. Adolescent<18 yr; lactation; pregnancy.
Special Precautions
Impaired hepatic function; G6PD deficiency; history of CNS disorders e.g. severe cerebral atherosclerosis, epilepsy. Avoid exposure to strong sunlight/sunlamp. Discontinue in case of pain, inflammation or rupture of tendon. Discontinue if phototoxicity or skin rash occurs. May impair ability to drive and operate machinery. Decrease incidence of drowsiness by taking at bedtime or with food. Perform liver function and pancreatic tests when symptoms develop. Increased risk of hepatotoxicity when used > 2 wk. Avoid rapid or bolus inj. Oral doses to be admin at least 2 hr before or 2 hr after magnesium or aluminum containing antacids, sucralfate, citric acid buffered with sodium citrate, metal cations (e.g. ferrous sulfate) and didanosine. IV morphine to be admin at least 2 hr after oral trovafloxacin in the fasted state and at least 4 hr after oral trovafloacin is taken with food.
Adverse Reactions
Dizziness, convulsions, increased intracranial pressure, CNS stimulation (e.g. tremor, restlessness, hallucinations), pseudomembranous colitis, phototoxicity, pancreatitis.
Potentially Fatal: Hapatotoxicity, anaphylactic reactions, severe hypotension, Stevens-Johnson syndrome.
Drug Interactions
Decreased oral absorption with antacids containing aluminum and magnesium salts, citric acid/sodium citrate, strontium, sucralfate, vitamins or minerals containing iron or zinc and concomitant admin of IV morphine. Increased risk of convulsions with NSAIDs. Increased anticoagulant effect with acenocoumarol, warfarin.
CIMS Class
ATC Classification
J01MA13 - trovafloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on trovafloxacin mesilate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in